Proliferative processes and features of tumor cell receptor apparatus of the breast carcinoma



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cell division in tumor tissue is associated not only with the growth rate of the tumor, but also its response to ongoing chemotherapy. The isolated subtypes of breast carcinoma differ significantly in the prognosis of the disease, but up to now the level of proliferative processes is only taken into account when dividing the Luminal variants. The aim of the study was to analyze the relationship between the level of proliferative processes in the tumor tissue of breast carcinoma in different tumor subtypes, analyze the patterns of proliferation activity and the characteristics of the receptor apparatus of cells. Material investigated 672 cases of breast invasive carcinomas. In all cases investigated by immunohistochemistry proliferative activity index Ki-67 tumor, as well as steroid hormone receptors ER, PR, and HER-2 / neu receptor. All the cases were divided into biological subtypes according to the standard classification. Mid proliferation index Ki-67 group luminal subtype tumors equaled 8,4±0,2%, in the luminal (HER-2 positive) subtype - 28,8±2,5%, in the luminal (HER-2 negative) subtype - 32,3±1,0%, HER-2 positive subtype - 39,0±2,2%, triple negative subtype - 54,6±2,1% tumors (p <0,05), with the exception of groups in luminal tumors (HER-2 negative) and In the luminal (HER-2 positive) biological subtypes (p> 0,05). Significant differences in proliferation between all treatment groups. The lowest level of proliferation characteristic luminal subtype of breast carcinoma (8.4%), most proliferating tumors are triple negative subtype (Ki-67 = 54.6%). The results show low proliferation of tumors in luminal A subtype of breast carcinoma, as well as a high tumor proliferation in such biological subtypes as luminal B (HER2-positive), luminal B (HER2-negative), HER2 positive and triple negative, and the highest level of expression of Ki-67 observed in carcinomas of triple negative subtype. The observed differences in proliferation levels determined by the expression level of Ki-67 between the subtypes of the breast cancer associated with differences in the receptor apparatus of tumor cells allow us not only to clarify the intracellular mechanisms of cell proliferation in tumor tissue, but also to recommend taking them into account as an additional diagnostic criterion for matching the level Proliferation of the receptor status of tumor cells within each of the subtypes of the breast cancer.

Full Text

Restricted Access

About the authors

S. V Sazonov

Institute for Medical Cell Technologies; Ural State Medical University

Email: prof-ssazonov@yandex.ru

A. A Brilliant

Institute for Medical Cell Technologies

Yu. M Brilliant

Institute for Medical Cell Technologies; Ural State Medical University

References

  1. Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Клинические рекомендации по диагностике и лечению рака молочной железы. Санкт-Петербург: АБВ-пресс; 2013.
  2. Бондарева В.А., Шпонька И.С. Значение прогностических маркеров опухолевой прогрессии Ki-67 и р53 в опухолях молочной железы. Морфология 2007; 1(1): 40-4.
  3. Sazonov S., Brilliant A., Brilliant Y. Proliferation of cancer stem cells in triple negative breast cancer. The Breast 2017; 32 Suppl 1: 29-30.
  4. Сазонов С.В. ИГХ диагностика рака молочной железы. Saarbrücken: LAP LAMBERT Academic Publishing; 2013.
  5. Penault-Llorca F., Cayre A., Mishellany F.B. et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int. J. Oncol. 2003; 22(6): 1319-25.
  6. Esposito A., Criscitiello C., Curigliano G. Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience 2015; 9: 518-29.
  7. Франк Г.А., Завалишина Л.Э., Пожарисский К.М. Рак молочной железы. М.: Практическая медицина; 2014.
  8. Фадеев Ф.А., Луговец Д.В., Улитко М.В. и др. Влияние состава ростовой среды и концентрации фетальной сыворотки на пролиферативную активность фибробластов. Гены и клетки 2016; 11(4): 75-9.
  9. Jalava P., Kuopio T., Juntti-Patinen L. et al. Ki-67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki-67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48(6): 674-82.
  10. Hammond M.E.H., Hayes D.F., Wolff A.C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of oncology practice 2010; 6(4): 195-7.
  11. Bilous M., Dowsett M., Hanna W. et al. Current Perspectives on HER2 Testing: A Review of National Testing Guidelines. Mod. Pathol. 2003; 16(2): 173-82.
  12. Yu Z., Ye S., Hu G. et al. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. Future Med. Chem. 2015; 7(3): 269-89.
  13. Новикова Е.А., Кодинцев А.Н., Сазонов С.В. и др. Экспрессия фермента топоизомераза-II альфа в молекулярно-генетических подтипах рака молочной железы. Вестник уральской медицинской академической науки 2016; 4: 30-7.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies